Oklahoma Medical Research Foundation

Other

Carl V Manion

Allen B Edmundson

It has now been found that N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester (APM) and/or one of its lower alkyl derivatives can be used to treat allergic contact dermatitis associated with irritating oils such as catechol-containing plant-derived antigens such as poison ivy, poison oak, poison sumac and Asian lacquer tree and oils containing capsaicin. Topical application of APM and/or derivative can reduce or alleviate the symptoms associated with irritation of the skin and/or mucous membranes caused by contact or inhalation of these oils or fumes from burning vegetation containing these oils.

Inhibition of allergic contact dermatitis by N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester

It has now been found that N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester (APM) lowers whole blood viscosity in patient, including those suffering from sickle cell disease and plasma cell dyscrasias. Upon in vivo APM treatment patients experienced a significant lowering of whole blood viscosity. In vitro addition of APM to patients samples having elevated whole blood viscosity resulted in reduced viscosity over time. These in vivo and in vivo results identify APM as a therapeutic agent for molecular diseases which lead to elevated whole blood viscosity. A method by which APM treatment can be monitored is also disclosed.

Viscosity modulating substance and use thereof

It has now been found that N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester (APM) exhibits antisickling properties. In vitro testing verified that APM significantly lowered the frequency of sickling of red blood cells from each of twelve pediatric aged patients being treated for sickle-cell anemia by exchange transfusion. Sickling was also inhibited in an &ldquo;index&rdquo; patient after oral administering of APM. These in vitro and in vivo results identify APM as a therapeutic agent for the family of sickle cell molecular diseases.

Inhibition or erythrocyte sickling by N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester

N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester and/or its derivatives has been found have appetite-stimulating effects in vertebrate animals. Preferably, it is administered by oral ingestion of either food, beverage, or food supplement.

N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester and its derivatives for appetite enhancement

N-L-&agr;-Aspartyl-L-phenylalanine 1-methyl ester (APM) and its derivatives have been found to effect disease regression in osteoarthritis, osteoporosis, and rheumatoid arthritis. APM performs as a TNF-&agr; antagonist as well as an antipyretic agent.

Use of N-L-&agr;-aspartyl-L-phenylalanine 1-methyl ester and its derivatives in disease regression

N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester and its derivatives

Analgesic use of N-L-.alpha.-aspartyl-L-phenylalanine 1-methyl ester

N-L-.alpha.-aspartyl-L-phenylalanine 1-methyl ester and/or its derivatives has been found to have analgesic pain relieving properties. It has been found to be especially effective in relieving pain associated with osteoarthritis and multiple sclerosis. It can be administered by itself or in combination with other analgesics. When given in combination with other analgesics, N-L-.alpha.-aspartyl-L-phenylalanine 1-methyl ester and/or its derivatives helps to alleviate the detrimental side effects of other analgesic medications by lowering the dosage requirements for pain relief.

Growing community of inventors

Oklahoma City, OK, United States of America

Carl V Manion